Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breaking through BCL-2 inhibition in CLL.

Blood - 5 Mar 2020

Chong Stephen J F, Davids Matthew S

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Leukemia, Lymphocytic, Chronic, B-Cell
Share to Mutation
Share to Proto-Oncogene Proteins c-bcl-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Sulfonamides

Source

Identifiers

PMID: 32135019
DOI: 10.1182/blood.2019004767

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breaking through BCL-2 inhibition in CLL.PMID 32135019Read ↗

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity Read ↗

Decoding and unlocking the BCL-2 dependency of cancer cellsSemantic proximity Read ↗

Bodyguards and assassins: Bcl‐2 family proteins and apoptosis control in chronic lymphocytic leukaemiaSemantic proximity Read ↗

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapiesSemantic proximity Read ↗

Targeting the B-Cell Lymphoma/Leukemia 2 Family in CancerSemantic proximity Read ↗

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin LymphomasSemantic proximity Read ↗

Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Attacking cancer's Achilles heel: antagonism of anti‐apoptotic <scp>BCL</scp>‐2 family membersSemantic proximity Read ↗

Therapeutics targeting Bcl-2 in hematological malignanciesSemantic proximity Read ↗

Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies – from pathogenesis to treatmentSemantic proximity Read ↗

Why anti-Bcl-2 clinical trials fail: a solutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.